The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia

被引：0
|
作者：
Keck, PE
Strakowski, SM
McElroy, SL
机构：
[1] Univ Cincinnati, Coll Med, Dept Psychiat, Biol Psychiat Program, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Coll Med, Dept Psychiat, Psychot Disorders Res Programs, Cincinnati, OH 45267 USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2000年 / 61卷
关键词：
D O I：
暂无
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
Depressive symptoms and syndromal depression commonly occur in patients with schizophrenia. Schizophrenia is also associated with aggression directed at self and others. For this article, the available literature regarding the efficacy of clozapine, risperidone, olanzapine, quetiapine, and ziprasidone in the treatment of depression, hostility, and suicidality in patients with schizophrenia was reviewed. These studies suggest that atypical antipsychotics may exert: therapeutic effects an depression and hostility as well as psychosis and that clozapine and olanzapine may reduce suicidality in patients with schizophrenia. These therapeutic actions appear to represent additional advantages of atypical antipsychotics compared with standard agents.
引用
收藏
页码：4 / 9
页数：6
相关论文
共 50 条
  • [21] Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms
    Lewis, R
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1998, 43 (06): : 596 - 604
  • [22] Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
    Lee, Kyoung-Uk
    Jeon, Yang-Whan
    Lee, Hae-Kook
    Jun, Tae-Youn
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (06) : 447 - 452
  • [23] Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
    Jun, T.
    Jeon, Y.
    Lee, H.
    Lee, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S486 - S486
  • [24] Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms
    Vahia, Ipsit V.
    Lanouette, Nicole M.
    Golshan, Shahrokh
    Fellows, Ian
    Mohamed, Somaia
    Kasckow, John W.
    Zisook, Sidney
    INDIAN JOURNAL OF PSYCHIATRY, 2013, 55 (02) : 144 - 148
  • [25] Basal cortisol concentrations and symptoms severity in patients with schizophrenia treated with atypical antipsychotics
    Wilczynski, K.
    Tobolska, D.
    Lorek, M.
    Mazgaj, E.
    Krysta, K.
    Krzystanek, M.
    Gawlik, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S422 - S423
  • [26] Comparative clinical efficacy of atypical antipsychotics and haloperidol in treatment of acute schizophrenia relapses
    Eremin, AV
    Kuzavkova, MV
    Mosolov, SN
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S132 - S132
  • [27] A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia
    Citrome, Leslie
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (11) : 1545 - 1573
  • [28] Atypical antipsychotics in schizophrenia; efficacy and effect on serotonergic parameters
    Tuinier, S
    Verhoeven, WMA
    van der Heijden, FMMA
    Sijben, AES
    EUROPEAN PSYCHIATRY, 2002, 17 : 189S - 189S
  • [29] Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs
    Liu, Keying
    Zhang, Bide
    Chen, Zhoufangyuan
    Chen, Fukun
    Li, Zexu
    Gao, Yunzhi
    Zhao, Yuechao
    Liu, Yihao
    Wang, Yanlong
    ANNALS OF GENERAL PSYCHIATRY, 2025, 24 (01)
  • [30] Treatment of suicidal risks in schizophrenia with atypical antipsychotics
    Timotijevic, IT
    Stefanovic, LS
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S246 - S246
12345